No Data
No Data
Kodiak Sciences Completes Enrollment In Second Registrational Trial Of Tarcocimab In Patients With Diabetic Retinopathy; Topline Clinical Data Of The Confirmatory Registrational Study GLOW2 Expected In Q1 2026
Express News | Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients With Diabetic Retinopathy
Kodiak Sciences Granted Orphan Designation for Tabirafusp Alfa
We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate
Kodiak Sciences Inc.'s (NASDAQ:KOD) Recent 20% Pullback Adds to One-year Year Losses, Institutional Owners May Take Drastic Measures
Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025